Fig. 5From: Development of anti-aflatoxin B1 nanobodies from a novel mutagenesis-derived synthetic library for traditional Chinese medicine and foods safety testingInteraction of nanobodies A1 and F2 with AFB1. Molecular docking was used to predict the interaction between the key residues of nanobodies A1 and F2 with AFB1. A The structure of the template nanobody 3QXV is shown by the cartoon diagram, including CDR-H1 (green), CDR-H2 (blue), CDR-H3 (magenta), CDR-H4 (orange), and N-terminal (NT) (yellow) loops. B, C Schematic representing all interactions between individual nanobodies A1(B) and F2(C) with AFB1. The interacting residues of a nanobody with AFB1 are present in the panel. The AFB1 molecule is shown as a stick model, and its carbon atoms are in pink. The interactions between the AFB1 molecule and the nanobody residues are represented by orange and magenta dotted lines, indicating cation-pi interaction and hydrophobic interactions, respectively. D The percentages of the binding of the serially diluted A1 and F2 nanobodies to AFB1 were calculated. The dashed lines indicate the nanobody concentration at EC50Back to article page